Certara, Inc. - Common Stock (CERT)
14.15
+0.62 (4.58%)
NASDAQ · Last Trade: Apr 18th, 9:05 AM EDT
Via Stocktwits · April 15, 2025
Via Benzinga · April 15, 2025
Certara reports $106M Q1 revenue, authorizes $100M buyback, and launches a new AI-driven non-animal testing tool to support biopharma innovation.
Via Benzinga · April 14, 2025
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.
Via Benzinga · April 13, 2025

Via Benzinga · November 7, 2024
FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency.
Via Benzinga · April 11, 2025
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · April 11, 2025
Via Benzinga · April 11, 2025
Via Benzinga · April 11, 2025
Via Benzinga · April 11, 2025
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · April 10, 2025
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing requirements.
Via Benzinga · April 10, 2025
Via Benzinga · April 10, 2025
Trump's new tariffs trigger selloff, framed as correction to trade imbalance. China faces 37% duties, EU 20%, Japan 24%. Tech stocks hit hard.
Via Benzinga · April 2, 2025

Via Benzinga · February 14, 2025

Via Benzinga · September 27, 2024

Via Benzinga · September 27, 2024

CERT stock results show that Certara missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024

CERT stock results show that Certara met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024